Do dimethyl fumarate and nicotinic acid elicit common, potentially HCA
HCA2
adverse drug reaction
dimethyl fumarate
nicotinic acid
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
revised:
03
02
2021
received:
05
07
2020
accepted:
12
02
2021
pubmed:
20
2
2021
medline:
28
10
2021
entrez:
19
2
2021
Statut:
ppublish
Résumé
Dimethyl fumarate and nicotinic acid activate the hydroxy-carboxylic acid receptor 2 (HCA We identified spontaneous reports of suspected ADRs to dimethyl fumarate and nicotinic acid in the European Adverse Drug Reaction Database (EudraVigilance). These reports were analysed at different hierarchical levels of the Medical Dictionary for Regulatory Activities (MedDRA). In addition, we screened murine organs for HCA Similarities in the ADR profile of dimethyl fumarate and nicotinic acid included "gastrointestinal signs and symptoms" (odds ratio [OR] 0.8 [0.6-1.1]), "hepatobiliary investigations" (OR 1.3 [0.7-2.5]) and "anxiety disorders and symptoms" (OR 0.9 [0.3-2.2]) in High Level Group Terms; "diarrhoea (excluding infective)" (OR 1.2 [0.7-1.8]) and "liver function analyses" (OR 1.3 [0.7-2.6]) in High Level Terms; and "diarrhoea" (OR 1.2 [0.7-2.0]) and "vomiting" (OR 0.9 [0.4-1.7]) in Preferred Terms. In analogy, HCA The gastrointestinal ADRs common to both substances may be mediated by HCA
Substances chimiques
Niacin
2679MF687A
Dimethyl Fumarate
FO2303MNI2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3813-3824Informations de copyright
© 2021 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Références
Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098-1107. https://doi.org/10.1056/NEJMoa1114287
Chen H, Assmann JC, Krenz A, et al. Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE. J Clin Invest. 2014;124(5):2188-2192. https://doi.org/10.1172/JCI72151
Parodi B, Rossi S, Morando S, et al. Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS. Acta Neuropathol. 130(2):279-295. https://doi.org/10.1007/s00401-015-1422-3
Offermanns S. Hydroxy-Carboxylic Acid Receptor Actions in Metabolism. Trends Endocrinol Metab. 2017;28(3):227-236. https://doi.org/10.1016/j.tem.2016.11.007
Deeks ED. Dimethyl Fumarate: A Review in Relapsing-Remitting MS. Drugs. 2016;76(2):243-254. https://doi.org/10.1007/s40265-015-0528-1
Food and Drug Administration. Tecfidera: full prescribing information. Published 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204063s020lbl.pdf. Accessed June 29, 2020.
Hanson J, Gille A, Offermanns S. Role of HCA(2) (GPR109A) in nicotinic acid and fumaric acid ester-induced effects on the skin. Pharmacol Ther. 2012;136(1):1-7. https://doi.org/10.1016/j.pharmthera.2012.06.003
Tunaru S, Kero J, Schaub A, et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med. 2003;9(3):352-355. https://doi.org/10.1038/nm824 nm824 [pii]
Maciejewski M, Lounkine E, Whitebread S, et al. Reverse translation of adverse event reports paves the way for de-risking preclinical off-targets. Elife. 2017;6:e25818. https://doi.org/10.7554/eLife.25818
Dubrall D, Just KS, Schmid M, Stingl JC, Sachs B. Adverse drug reactions in older adults: a retrospective comparative analysis of spontaneous reports to the German Federal Institute for Drugs and Medical Devices. BMC Pharmacol Toxicol. 2020;21(1):25. https://doi.org/10.1186/s40360-020-0392-9
MedDRA. Introductory Guide MedDRA Version 23.0, March 2020. Published 2020. https://www.meddra.org/sites/default/files/guidance/file/intguide_23_0_english.pdf. Accessed June 29, 2020.
Alexander SPH, Christopoulos A, Davenport AP, et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. Br J Pharmacol. 2019;176(S1):S21-S141. https://doi.org/10.1111/bph.14748
Hanson J, Gille A, Zwykiel S, et al. Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice. J Clin Invest. 2010;120(8):2910-2919. https://doi.org/10.1172/jci42273
Kamanna VS, Ganji SH, Kashyap ML. The mechanism and mitigation of niacin-induced flushing. Int J Clin Pract. 2009;63(9):1369-1377. https://doi.org/10.1111/j.1742-1241.2009.02099.x
European Medicines Agency. Tecfidera. Product information. Published 2020. https://www.ema.europa.eu/en/medicines/human/EPAR/tecfidera. Accessed June 29, 2020.
Food and Drug Administration. Niaspan. Full prescribing information. Published 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020381Orig1s051lbl.pdf. Accessed June 29, 2020.
Rastogi V, Singh D, Mazza JJ, Parajuli D, Yale SH. Flushing Disorders Associated with Gastrointestinal Symptoms: Part 1, Neuroendocrine Tumors, Mast Cell Disorders and Hyperbasophila. Clin Med Res. 2018;16(1-2):16-28. https://doi.org/10.3121/cmr.2017.1379a
Surawicz CM. Mechanisms of diarrhea. Curr Gastroenterol Rep. 2010;12(4):236-241. https://doi.org/10.1007/s11894-010-0113-4
Rivière PJ, Farmer SC, Burks TF, Porreca F. Prostaglandin E2-induced diarrhea in mice: importance of colonic secretion. J Pharmacol Exp Ther. 1991;256(2):547-552.
Marrie RA, Reingold S, Cohen J, et al. The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. Mult Scler Houndmills Basingstoke Engl. 2015;21(3):305-317. https://doi.org/10.1177/1352458514564487
Tully PJ, Harrison NJ, Cheung P, Cosh S. Anxiety and Cardiovascular Disease Risk: a Review. Curr Cardiol Rep. 2016;18(12):120. https://doi.org/10.1007/s11886-016-0800-3
European Medicines Agency. Tredaptive product information. Published 2013. https://www.ema.europa.eu/en/documents/product-information/tredaptive-epar-product-information_en.pdf. Accessed June 29, 2020.
Gasim M, Bernstein CN, Graff LA, et al. Adverse psychiatric effects of disease-modifying therapies in multiple sclerosis: A systematic review. Mult Scler Relat Disord. 2018;26:124-156. https://doi.org/10.1016/j.msard.2018.09.008
Rahman M, Muhammad S, Khan MA, et al. The beta-hydroxybutyrate receptor HCA2 activates a neuroprotective subset of macrophages. Nat Commun. 2014;5(1):3944. https://doi.org/10.1038/ncomms4944
Sild M, Ruthazer ES, Booij L. Major depressive disorder and anxiety disorders from the glial perspective: Etiological mechanisms, intervention and monitoring. Neurosci Biobehav Rev. 2017;83:474-488. https://doi.org/10.1016/j.neubiorev.2017.09.014
Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087-1097. https://doi.org/10.1056/NEJMoa1206328
Munoz MA, Kulick CG, Kortepeter CM, Levin RL, Avigan MI. Liver injury associated with dimethyl fumarate in multiple sclerosis patients. Mult Scler. 2017;23(14):1947-1949. https://doi.org/10.1177/1352458516688351
Jüngst C, Kim Y-J, Lammert F. Severe drug-induced liver injury related to therapy with dimethyl fumarate: Hepatology, Vol. XX, No. X, 2016 Jüngst, Kim, and Lammert. Hepatology. 2016;64(4):1367-1369. https://doi.org/10.1002/hep.28652
Bhardwaj SS, Chalasani N. Lipid-lowering agents that cause drug-induced hepatotoxicity. Clin Liver Dis. 2007;11(3):597-613vii. https://doi.org/10.1016/j.cld.2007.06.010
Jadeja RN, Jones MA, Fromal O, et al. Loss of GPR109A/HCAR2 induces aging-associated hepatic steatosis. Aging. 11(2):386-400. https://doi.org/10.18632/aging.101743
Shomali T, Mosleh N, Kamalpour M. Screening of Different Organs of Rats for HCA2 Receptor mRNA. Int J Mol Cell Med. 2014;3(2):126-129.
European Medicines Agency. Skilarence. Product information. Published 2019. https://www.ema.europa.eu/en/medicines/human/EPAR/skilarence. Accessed June 29, 2020.
Biogen. Fachinformation für Fumaderm® initial/Fumaderm. Published 2020. https://www.fachinfo.de/suche/fi/000847. Accessed June 29, 2020.
O'Brien T, Silverberg JD, Nguyen TT. Nicotinic acid-induced toxicity associated with cytopenia and decreased levels of thyroxine-binding globulin. Mayo Clin Proc. 1992;67(5):465-468. https://doi.org/10.1016/s0025-6196(12)60393-0
Treumer F, Zhu K, Gläser R, Mrowietz U. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol. 2003;121(6):1383-1388. https://doi.org/10.1111/j.1523-1747.2003.12605.x
Anderson TJ, Boden WE, Desvigne-Nickens P, et al. Safety profile of extended-release niacin in the AIM-HIGH trial. N Engl J Med. 2014;371(3):288-290. https://doi.org/10.1056/NEJMc1311039
HPS Thrive Collaborative Group, Landray MJ, Haynes R, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203-212. https://doi.org/10.1056/NEJMoa1300955
McKenney J, Bays H, Gleim G, et al. Safety and tolerability of extended-release niacin-laropiprant: Pooled analyses for 11,310 patients in 12 controlled clinical trials. J Clin Lipidol. 2015;9(3):313-325. https://doi.org/10.1016/j.jacl.2015.02.006
Graff EC, Fang H, Wanders D, Judd RL. Anti-inflammatory effects of the hydroxycarboxylic acid receptor 2. Metabolism. 2016;65(2):102-113. https://doi.org/10.1016/j.metabol.2015.10.001
Goldie C, Taylor AJ, Nguyen P, McCoy C, Zhao X-Q, Preiss D. Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials. Heart. 2016;102(3):198-203. https://doi.org/10.1136/heartjnl-2015-308055
Blond E, Rieusset J, Alligier M, et al. Nicotinic acid effects on insulin sensitivity and hepatic lipid metabolism: an in vivo to in vitro study. Horm Metab Res Horm Stoffwechselforschung Horm Metab. 2014;46(6):390-396. https://doi.org/10.1055/s-0034-1372600
Wong TP, Chan LK, Leung PS. Involvement of the Niacin Receptor GPR109a in the LocalControl of Glucose Uptake in Small Intestine of Type 2Diabetic Mice. Nutrients. 2015;7(9):7543-7561. https://doi.org/10.3390/nu7095352
Chen L, So WY, Li SY, Cheng Q, Boucher BJ, Leung PS. Niacin-induced hyperglycemia is partially mediated via niacin receptor GPR109a in pancreatic islets. Mol Cell Endocrinol. 2015;404(0):56-66. https://doi.org/10.1016/j.mce.2015.01.029
Matzinger M, Fischhuber K, Heiss EH. Activation of Nrf2 signaling by natural products-can it alleviate diabetes? Biotechnol Adv. 2018;36(6):1738-1767. https://doi.org/10.1016/j.biotechadv.2017.12.015
Saidu NEB, Kavian N, Leroy K, et al. Dimethyl fumarate, a two-edged drug: Current status and future directions. Med Res Rev. 2019;39(5):1923-1952. https://doi.org/10.1002/med.21567
Tuteja S. Activation of HCAR2 by niacin: benefits beyond lipid lowering. Pharmacogenomics. 2019;20(16):1143-1150. https://doi.org/10.2217/pgs-2019-0092